IN THE CLAIMS

1-99 (Canceled)

100. (Previously Presented) A method for treating hemophilia B in a mammal, comprising:

administering recombinant adeno-associated virus (rAAV) particles to a mammalian liver cell, wherein said rAAV particles consist essentially of AAV terminal repeats flanking a MFG promoter, adjacent MLV intervening sequence including the splice donor and acceptor sites and env ATG, a polynucleotide encoding Factor IX operably linked to said MFG promoter, and a bovine growth hormone polyA sequence, wherein following infection of said mammalian cells, Factor IX protein is expressed in the liver.

101. (Previously Presented) The method of Claim 100, wherein said Factor IX protein is diffusible and is delivered to the circulating blood.

102 - 104. (Canceled)

105. (Previously Presented) The method of Claim 100, wherein said administering comprises injecting said rAAV into the portal vasculature of said mammal.

106. (Previously Presented) The method of Claim 100, wherein said administering comprises injecting said rAAV intravenously into said mammal.

107 - 108. (Canceled)

109. (Previously Presented) A pharmaceutical composition for treating a hemophilia B comprising, (a) recombinant adeno-associated virus (rAAV) particles consisting essentially of AAV terminal repeats flanking a MFG promoter, adjacent MLV intervening sequence including the splice donor and acceptor sites and env ATG, a polynucleotide encoding Factor IX operably linked to the MFG promoter, a bovine growth hormone polyA sequence, and (b) a pharmaceutically acceptable carrier.

110 - 119. (Canceled)